Evidence map›Paper›PMID 36430423›Full record

ArticleInternational journal of molecular sciences2022

Effect of Quercetin and Fingolimod, Alone or in Combination, on the Sphingolipid Metabolism in HepG2 Cells.

Albena Momchilova, Georgi Nikolaev, Stefan Pankov, Evgenia Vassileva, Nikolai Krastev, Bozhil Robev, Dimo Krastev, Adriana Pinkas, Roumen Pankov

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Albena MomchilovaInstitute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
Georgi NikolaevBiological Faculty, Sofia University "St. Kliment Ohridki", 8 Dragan Tzankov Str., 1164 Sofia, Bulgaria.ORCID 0000-0003-0584-415X
Stefan PankovInstitute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
Evgenia VassilevaClinic of Neurology, Tsaritsa Yoanna University Hospital-ISUL, 1527 Sofia, Bulgaria.
Nikolai KrastevDepartment of Anatomy, Histology and Embryology, Medical University-Sofia, Blvd. Sv. Georgi Sofiisky 1, 1431 Sofia, Bulgaria.
Bozhil RobevDepartment of Medical Oncology, University Multi-Profile Hospital for Active Treatment (UMHAT) "St. Ivan Rilski", 1606 Sofia, Bulgaria.
Dimo KrastevMedical College "Y. Filaretova", Medical University-Sofia, Yordanka Filaretova Str. 3, 1606 Sofia, Bulgaria.
Adriana PinkasCSTEP, Office of Continuing Education, Suffolk County Community College 30 Greene Ave., Sayville, NY 11782, USA.
Roumen PankovBiological Faculty, Sofia University "St. Kliment Ohridki", 8 Dragan Tzankov Str., 1164 Sofia, Bulgaria.
Bulgarian Academy of Sciences · BGMedical University of Sofia · BGSofia University "St. Kliment Ohridski" · BGQueen Giovanna Hospital · BGSuffolk County Community College · USUniversity Hospital St. Ivan Rilski · BG

Funding

Bulgarian Ministry of Education and Science Contract DО1-154/28/08/2018
6 · The paper itself

Abstract

Combinations of anti-cancer drugs can overcome resistance to therapy and provide new more effective treatments. In this work we have analyzed the effect of the polyphenol quercetin and the anti-cancer sphingosine analog fingolimod on the sphingolipid metabolism in HepG2 cells, since sphingolipids are recognized as mediators of cell proliferation and apoptosis in cancer cells. Treatment of hepatocellular carcinoma HepG2 cells with quercetin and fingolimod, alone or in combination, induced different degrees of sphingomyelin (SM) reduction and a corresponding activation of neutral sphingomyelinase (nSMase). Western blot analysis showed that only treatments containing quercetin induced up-regulation of nSMase expression. The same treatment caused elevation of ceramide (CER) levels, whereas the observed alterations in sphingosine (SPH) content were not statistically significant. The two tested drugs induced a reduction of the pro-proliferative sphingolipid, sphingosine 1 phosphate (S1P), in the following order: quercetin, fingolimod, quercetin + fingolimod. The activity of the enzyme responsible for CER hydrolysis, alkaline ceramidase (ALCER) was down-regulated only in the incubations involving quercetin and fingolimod did not affect this activity. The enzyme, maintaining the balance between apoptosis and proliferation, sphingosine kinase 1 (SK1), was down-regulated by incubations in the following order: quercetin, fingolimod, quercetin + fingolimod. Western blot analysis showed down-regulation in SK1 expression upon quercetin but not upon fingolimod treatment. Studies on the effect of quercetin and fingolimod on the two proteins associated with apoptotic events, AKT and Bcl-2, showed that only quercetin, alone or in combination, down-regulated the activity of the two proteins. The reported observations provide information which can be useful in the search of novel anti-tumor approaches, aiming at optimization of the therapeutic effect and maximal preservation of healthy tissues.

Indexed as

Fingolimod HydrochlorideSphingosineCeramidesHep G2 CellsHumansQuercetinSphingolipidsCeramidesFingolimod HydrochlorideQuercetinSphingolipidsSphingosineceramidefingolimodHepG2 cellsquercetinsphingolipid metabolismsphingosine-1-phosphate

Identifiers

PMID36430423
PMCPMC9697772
OpenAlexW4309009989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.